Strontium ranelate related Stevens-Johnson syndrome: a case report
Autor: | Chiung-Mei Chen, Chih-Hsun Yang, Y.-H. Hsiao, Wen-Hung Chung, H.-Y. Wang, H.-L. Hsiao |
---|---|
Rok vydání: | 2013 |
Předmět: |
medicine.medical_specialty
Endocrinology Diabetes and Metabolism Osteoporosis Thiophenes Strontium ranelate Internal medicine Medicine Eosinophilia Humans Osteoporosis Postmenopausal Aged Bone Density Conservation Agents business.industry Stevens johnson medicine.disease Dermatology Toxic epidermal necrolysis Rheumatology Surgery Methylprednisolone Stevens-Johnson Syndrome Itching Female Drug Eruptions medicine.symptom business medicine.drug |
Zdroj: | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 25(6) |
ISSN: | 1433-2965 |
Popis: | Strontium ranelate is a relatively new medication with good safety profile for the treatment of postmenopausal osteoporosis. However, severe cutaneous adverse drug reactions have been reported, such as drug rash with eosinophilia and systemic symptoms (DRESS), Stevens–Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). We report the case of a 70-year-old woman who developed multiple itching erythematous macules and plaques about 1 month after beginning strontium ranelate medication. The cutaneous lesions progressed over the entire body with severe oral and ocular mucosa involvement. Probable mild SJS was diagnosed, compatible with the pathology findings, and strontium ranelate was discontinued immediately. Systemic methylprednisolone was administered to suppress the overactive immune system and ameliorate cutaneous symptoms. With early recognition and prompt treatment, the patient’s prognosis was good. |
Databáze: | OpenAIRE |
Externí odkaz: |